Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says

Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.